Erasca News

Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating

TipRanksApr 3 13:47

Erasca Analyst Ratings

BenzingaApr 3 00:15

Erasca's Strong Clinical Data and Enhanced Financial Position Support Buy Rating

TipRanksMar 29 06:35

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)

TipRanksMar 28 18:21

Erasca Analyst Ratings

BenzingaMar 28 18:12

Erasca Analyst Ratings

BenzingaMar 11 21:58

Erasca's Strategic Oncology Focus and Pipeline Potential: An Overweight Rating With a Bright Outlook

TipRanksMar 11 19:15

B of A Securities Downgrades Erasca to Neutral, Lowers Price Target to $6

BenzingaJan 5 22:13

Erasca Analyst Ratings

BenzingaJan 5 22:12

Strong Buy Rating for Erasca's Stock on FDA Fast Track Designation and Market Expansion Potential

TipRanksDec 13, 2023 17:15

Mizuho Maintains Buy on Erasca, Lowers Price Target to $7

BenzingaNov 30, 2023 01:14

Erasca Analyst Ratings

BenzingaNov 30, 2023 01:13

Erasca Analyst Ratings

BenzingaNov 29, 2023 00:12

Erasca's Strategic Focus on MAPK Pathway in SEACRAFT-2 Study Warrants a Buy Rating

TipRanksNov 28, 2023 23:55

HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating

MT NewswiresNov 28, 2023 23:52

Erasca's Promising Future: Data Timelines, Financial Stability, and Fast-to-Market Opportunities Support Buy Rating

TipRanksNov 11, 2023 00:30

Promising Future Growth and Clinical Milestones: A Buy Rating for Erasca

TipRanksNov 10, 2023 07:55

HC Wainwright & Co. Initiates Coverage On Erasca With Buy Rating, Announces Price Target of $10

BenzingaOct 11, 2023 19:22

Erasca Analyst Ratings

BenzingaOct 11, 2023 19:20

Mizuho Securities Sticks to Their Buy Rating for Erasca (ERAS)

TipRanksAug 30, 2023 01:15